Raphaël Porcher

//Raphaël Porcher
Raphaël Porcher2019-01-11T14:38:11+00:00
Raphael Porcher

Raphaël Porcher, PhD

I am an Associate Professor of Biostatistics at Paris Descartes University, co-director of the Centre Virchow-Villermé Paris Berlin, and member of the METHODS team of CRESS-UMR1153. As a biostatistician, I am involved both in methodological and statistical research, as well as in applied clinical research, including clinical trials, observational studies and prognostic studies. I am a member of the Comité d’Evaluation Ethique / Institutional Review Board of Inserm.

I am also Senior Associate Editor for Methods at Clinical Orthopaedics and Related Research, and Associate Editor for Modeling Outcomes at the Journal of Hepatology.

Orcid number : 0000-0002-5277-4679

Research interests

  • Methods for personalized medicine, including statistical methods for the identification of optimal treatment regimes using randomized, large observational and routinely collected data

  • Estimation of the treatment effect in complex study designs, including causal inference for observational and randomized studies, real-life data, time-fixed and time-varying interventions

  • Evidence mapping and complex system methods in meta-research

Best publications

  • Porcher R, Jacot J, Wunder J,S Biau DJ. Identifying treatment responders using counterfactual modeling and potential outcomes. Statistical Methods in Medical Research 2018 (doi: 10.1177/0962280218804569).

  • Vivot A, Créquit P, Porcher R. Use of late-life expectancy for assessing the long-term benefit of immune checkpoint inhibitors. Journal of the National Cancer Institute 2019 (doi: 10.1093/jnci/djy211).

  • Harhay MO, Porcher R, Thabut G, Crowther MJ, DiSanto T, Rubin S, Penfil Z, Bing Z, Christie JD, Diamond JM, Cantu E. Donor lung sequence number and survival after lung transplantation in the United States. Annals of the American Thoracic Society 2018 (doi: 10.1513/AnnalsATS.201802-100OC).

  • Vo TT, Vivot A, Porcher R. Impact of biomarker-based design strategies on the risk of false-positive findings in targeted therapy evaluation. Clinical Cancer Research 2018;24:6257-6264.

  • Atal I, Trinquart L, Ravaud P, Porcher R. A mapping of 115,000 randomized trials revealed a mismatch between research effort and health needs in non-high-income regions. Journal of Clinical Epidemiology 2018;98:123-32.

  • Vivot A, Jacot J, Zeitoun JD, Ravaud P, Crequit P, Porcher R. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015. Ann Oncol. 2017 May 1;28(5):1111-1116. doi: 10.1093/annonc/mdx053.

  • Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials. J Clin Oncol. 2016 May 20;34(15):1813-9. doi: 10.1200/JCO.2015.64.2488.

  • Porcher R, Leyrat C, Baron G, Giraudeau B, Boutron I. Performance of principal scores to estimate the marginal compliers causal effect of an intervention. Stat
    Med. 2016 Feb 28;35(5):752-67. doi: 10.1002/sim.6735.

Links